Cytokine & CAM Antagonists: Janus Associated Kinase (JAK) Inhibitors - Washington

Prior Authorization Request Form

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826.**

This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance Information (if any):		

Is the requested medication: □ New or □ Continuation of Therapy? If continuation, list start date: _____

Is this patient currently hospitalized? □ Yes □ No If recently discharged, list discharge date: _____

Section B - Provider Information

First Name:		Last Name:		M.D./D.O.
Address:		City:	State:	ZIP code:
Phone:	Fax:	NPI #:	Specialty:	
Office Contact Name / Fax attention to:				

Section C - Medical Information

Medication:	**Strength:**
Directions for use:	**Quantity:**
Diagnosis (Please be specific & provide as much information as possible)**:**	**ICD-10 CODE:**

Is this member pregnant? □ Yes □ No If yes, what is this member's due date? _____

Section D – Previous Medication Trials

Medication Name	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs: Please refer to the patient's PDL for a list of preferred alternatives

United Healthcare Community Plan

Cytokine & CAM Antagonists: Janus Associated Kinase (JAK) Inhibitors - Washington

Prior Authorization Request Form

Member First name:	Member Last name:	Member DOB:

Clinical and Drug Specific Information

1. Is this request for a continuation of therapy? ☐ Yes ☐ No
   If yes, does patient have clinical documentation demonstrating disease stability or a positive clinical response? ☐ Yes ☐ No

2. Is this prescribed by, or in consultation with, any of the following? Check all that apply:
   ☐ Allergist ☐ Dermatologist ☐ Gastroenterologist
   ☐ Immunologist ☐ Rheumatologist ☐ Other. Specify: _____

3. Will the requested medication be used in combination with another Cytokine and CAM medication?
   ☐ Yes ☐ No

4. If request is non-preferred, has patient had treatment with one or more preferred Cytokine and CAM medications on the Apple Health Preferred Drug List (AHPDL) that was ineffective, contraindicated or not tolerated?

☐ Yes. List each medication and duration of trial:

Medication Name: _____ Duration: _____
Medication Name: _____ Duration: _____
Medication Name: _____ Duration: _____

☐ No. Explain why a preferred product(s) have not been tried: _____

5. What is patient current weight: _____kg Date taken: _____

6. Indicate patient's diagnosis and answer the associated questions as indicated:
   ☐ Alopecia areata (questions 7 - 10)
   ☐ Ankylosing Spondylitis (questions 11 - 15)
   ☐ Atopic dermatitis (questions 16 – 20)
   ☐ Crohn's Disease (questions 21 - 23)
   ☐ Non-radiographic axial spondyloarthritis (questions 11 - 15)
   ☐ Plaque Psoriasis (questions 24 – 28)
   ☐ Polyarticular Juvenile Idiopathic Arthritis (questions 29 – 30)
   ☐ Psoriatic Arthritis (PsA) (questions 31 - 34)
   ☐ Rheumatoid Arthritis (questions 35 -37)
   ☐ Ulcerative Colitis (questions 38 – 40)

For diagnosis of Alopecia areata

7. Is patient's current episode of alopecia areata lasting more than 6 months? ☐ Yes ☐ No

8. Has patient had ≥50% of the scalp hair loss (Severity of Alopecia Tool [SALT] score >50%)? ☐ Yes ☐ No

9. Does patient have a history of failure, contraindication, or intolerance to any of the following? Check all that apply:

☐ High-potency topical corticosteroids [minimum trial of 6 weeks]
☐ Intralesional corticosteroids [minimum trial of 6 weeks]
☐ Systemic therapy (i.e., oral corticosteroids, methotrexate, cyclosporine) [minimum trial of 6 weeks].

10. **For continuation of therapy:** Has documentation been submitted demonstrating a positive clinical response?

☐ Yes ☐ No

For diagnosis of Ankylosing Spondylitis or Non-radiographic axial spondyloarthritis:

11. Does patient have high disease activity as indicated by one of the following?

☐ Bath Ankylosing Disease Activity Index (BASDAI) score of at least 4
☐ Ankylosing Spondylitis Disease Activity Score (ASDAS) score of at least 2.1

12. Has patient had treatment with at least two different NSAIDs that has been ineffective, contraindicated or not tolerated [minimum trial of four weeks]? ☐ Yes ☐ No

13. Has patient's disease manifested as one of the following?

☐ Axial disease ☐ Peripheral arthritis

14. Has patient had treatment with at least one non-Cytokine and CAM disease-modifying antirheumatic drug (DMARD) that has been ineffective, contraindicated or not tolerated [minimum trial of 3 months]?

☐ Yes ☐ No

15. **For continuation of therapy:** Has documentation been submitted demonstrating disease stability or a positive clinical response (e.g., decrease in BASDAI or ASDAS score)? ☐ Yes ☐ No

For diagnosis of Atopic dermatitis:

16. Indicate disease severity for patient. Check all that apply:

☐ Body surface area (BSA) involvement of at least 10%
☐ Involvement of sensitive skin areas such as hands, feet, face, neck, genitalia, or intertriginous areas
☐ Disease severity scale scoring demonstrating severe chronic atopic dermatitis (e.g., Investigator's Global Assessment (IGA) score of 3 or greater; Eczema Area and Severity Index (EASI), Patient Oriented Eczema Measure (POEM), etc.)
☐ Other. Explain:

17. Indicate if patient is experiencing functional impairment, due to atopic dermatitis, of any of the following. Check all that apply:

☐ Activities of daily living (ADLs)
☐ Skin infections
☐ Sleep disturbances
☐ Other. Specify:

18. Has patient had a history of failure, defined as the inability to achieve or maintain remission, to any of the following, unless all are contraindicated or clinically inappropriate [minimum trial of 28-days each]? Check all that apply:

☐ Topical corticosteroids of at least medium/moderate potency (e.g. clobetasol, betamethasone, halobetasol)
☐ Topical calcineurin inhibitors (e.g. pimecrolimus cream, tacrolimus ointment)
☐ Topical PDE-4 inhibitors (e.g. crisaborole)
☐ All are contraindicated or clinically inappropriate. Explain:

19. Has treatment with dupilumab (Dupixent) has been ineffective, contraindicated, or not tolerated [minimum trial of 16 weeks]? ☐ Yes ☐ No

20. **For continuation of therapy:** Has documentation been submitted demonstrating disease stability or a positive clinical response as defined by any of the following? Check all that apply:
☐ Reduction in body surface area involvement of at least 20%
☐ Achieved or maintained clear or minimal disease from baseline (equivalent to IGA score of 0 or 1)
☐ Experienced or maintained a decrease in EASI score of at least 50%
☐ Improvement in functional impairment (e.g., improvement in ADLs, skin infections, or sleep disturbance)

For diagnosis of Crohn's Disease (CD)

21. Has treatment with any of the following conventional therapies that have been ineffective, contraindicated, or not tolerated? Check all that apply:
☐ Oral corticosteroids (e.g., prednisone, methylprednisolone) used short-term to induce remission or alleviate signs/symptoms of disease flare
☐ Immunomodulatory agent (e.g., methotrexate, azathioprine, 6-mercaptopurine) [minimum trial of 12 weeks]

22. Does patient have documentation of high-risk disease (e.g., symptoms despite conventional therapy, obstruction, abscess, stricture, phlegmon, fistulas, resection, extensive bowel involvement, early age of onset, growth retardation, Crohn's Disease Activity Index (CDAI) > 450, Harvey-Bradshaw index > 7)?
☐ Yes ☐ No

23. **For continuation of therapy:** Has documentation been submitted demonstrating disease stability or a positive clinical response (e.g., improvement in endoscopic activity, taper or discontinuation of corticosteroids, reduction in number of liquid stools, decrease in presence and severity of abdominal pain, decrease in CDAI, decrease in Harvey-Bradshaw index)? ☐ Yes ☐ No

For diagnosis of Plaque Psoriasis

24. Does patient have presence of ongoing disease for greater than 6 months? ☐ Yes ☐ No

25. Please indicate the following for patient:
☐ Disease affects at least 10% body surface area ☐ Disease affects the face, ears, hands, feet, or genitalia

26. Have baseline assessments been submitted (e.g., body surface area (BSA), Psoriasis Area and Severity Index (PASI), Psoriasis Physician's Global Assessment (PGA), itch numeric rating scale, etc.)?
☐ Yes ☐ No

27. Has patient had a history of failure, contraindication, or intolerance to the following? Check all that apply:
☐ Phototherapy (UVB or PUVA) [minimum trial of 12 weeks]
☐ Treatment with at least one non-Cytokine and CAM DMARD (e.g., methotrexate, cyclosporine, acitretin, azathioprine, etc.) [minimum trial of 12 weeks]

28. **For continuation of therapy:** Has documentation been submitted demonstrating disease stability or a positive clinical response (e.g., improvement in BSA, PSAI, Psoriasis PGA, itch numeric rating scale)?
☐ Yes ☐ No

For diagnosis of Polyarticular Juvenile Idiopathic Arthritis

29. Has patient had treatment with at least one non-Cytokine and CAM DMARD (e.g., methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, azathioprine, cyclosporine) that has been ineffective, unless all are contraindicated, or not tolerated [minimum trial of 3 months]? ☐ Yes ☐ No

30. **For continuation of therapy:** Has documentation been submitted demonstrating disease stability or a positive clinical response (e.g., improvement in joint pain, swelling, activities of daily living, reduction in diseases flares, etc.)? ☐ Yes ☐ No

For diagnosis of Psoriatic Arthritis

31. Has patient had treatment with at least one non-Cytokine and CAM disease-modifying antirheumatic drug (DMARD) that has been ineffective, contraindicated or not tolerated [minimum trial of 3 months]?

☐ Yes ☐ No

32. Does patient have presence of active, severe disease indicated by provider assessment?

☐ Yes ☐ No

33. Does patient have presence of any of the following? Check all that apply:

☐ Erosive disease
☐ Elevated C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR)
☐ Long-term damage interfering with function (e.g., joint deformities, vision loss)
☐ Major impairment of quality of life due to high disease activity at many sites (including dactylitis, enthesitis) or functionally limiting arthritis at a few sites.

34. **For continuation of therapy:** Has documentation been submitted demonstrating disease stability or a positive clinical response (e.g., improvement in joint pain, swelling, activities of daily living, reduction in diseases flares, etc.)? ☐ Yes ☐ No

For diagnosis of Rheumatoid Arthritis (RA)

35. Have baseline assessments been submitted (e.g., Disease Activity Score for 28 joints (DAS28) with the CRP, DAS28 with ESR, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Routine Assessment of Patient Index Data 3 (RAPID3), Patient Activity Scale (PAS) II? ☐ Yes ☐ No

36. Has patient had treatment with at least one non-Cytokine and CAM DMARD (e.g., methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine, azathioprine) that has been ineffective, unless all are contraindicated, or not tolerated [minimum trial of 3 months]? ☐ Yes ☐ No

37. **For continuation of therapy:** Has documentation been submitted demonstrating disease stability or a positive clinical response (e.g. improvement in DAS28 with CRP/ESR, SDAI, CDAI, RAPID3, PAS II scores)?

☐ Yes ☐ No

For diagnosis of Ulcerative Colitis

38. Have baseline assessments been submitted (e.g., stool frequency, endoscopy results, presence of rectal bleeding, disease activity scoring tool)? ☐ Yes ☐ No

39. Has treatment with conventional therapy (e.g., systemic corticosteroids, azathioprine, mesalamine, sulfasalazine) been ineffective, unless all are contraindicated, or not tolerated [minimum trial of 12 weeks]?

☐ Yes ☐ No

40. **For continuation of therapy:** Has documentation been submitted demonstrating disease stability or a positive clinical response (e.g., decreased stool frequency, decreased rectal bleeding, improvement in

endoscopic activity, tapering or discontinuation of corticosteroid therapy, or improvement on a disease activity scoring tool)?

☐ Yes ☐ No

CHART NOTES ARE REQUIRED WITH THIS REQUEST		
Prescriber signature	Prescriber specialty	Date